Topiramate

Drug Profile

Topiramate

Alternative Names: Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topamax Migraine; Topimax; Topina; Topina fine granules

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Inc; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Kyowa Hakko Kirin; Ortho-McNeil; Xian-Janssen
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; GABA-A receptor antagonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Lennox-Gastaut syndrome; Migraine
  • Phase III Obesity
  • Clinical Phase Unknown Post-traumatic stress disorders
  • Discontinued Bipolar disorders; Diabetic neuropathies

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Feb 2016 Phase-III clinical trials in Obesity (In adolescents, In children) in France (PO) (EudraCT2011-006193-36)
  • 28 Mar 2015 Launched for Migraine (In adolescents, Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top